Watch List for Investors: Equus Total Return (NYSE:EQS), Fifth Third Bancorp (NASDAQ:FITB), MasTec (NYSE:MTZ), ContraVir Pharmaceuticals (NASDAQ:CTRV)

Posted by on Apr 29, 2016

Hudson Global, Inc (NASDAQ:HSON) shares advanced 5.26% in last trading session and ended the day at $2.60. HSON Gross Margin is 40.50% and its has a return on assets of 1.80%. Hudson Global, Inc (NASDAQ:HSON) quarterly performance is -3.38%.

Hudson Global, Inc (NASDAQ:HSON) reported On a retained basis, gross margin of $41.3 million declined 5.7 percent from the first quarter of 2015 and 1.3 percent in constant currency. On a reported basis, gross margin declined 13.9 percent or 10.1 percent in constant currency. Adjusted EBITDA loss of $2.0 million, including $0.5 million of legal fees related to an arbitration matter, compared with adjusted EBITDA loss of $3.8 million in the first quarter of 2015.

Equus Total Return, Inc. (NYSE:EQS) ended the last trading day at $1.76. Company weekly volatility is calculated as 2.85% and price to cash ratio as 1.29. Equus Total Return, Inc. (NYSE:EQS) showed a weekly performance of 6.03%.

On 28 April, Fifth Third Bancorp (NASDAQ:FITB) shares fell -1.28% and was closed at $18.49. FITB EPS growth in last 5 year was 26.30%. Fifth Third Bancorp (NASDAQ:FITB) year to date (YTD) performance is -7.30%.

Fifth Third Bancorp (NASDAQ:FITB) is introducing a Consumer Directed Healthcare Solution, making it easier for business customers to administer high-deductible health plans paired with tax-advantaged financial accounts such as a Health Savings Account (HSA), Flexible Spending Account (FSA) and a Health Reimbursement Arrangement (HRA).

MasTec, Inc. (NYSE:MTZ) shares fell -1.71% in last trading session and ended the day at $23.06. MTZ Gross Margin is 11.60% and its has a return on assets of -2.50%. MasTec, Inc. (NYSE:MTZ) quarterly performance is 57.95%.

MasTec, Inc. (NYSE: MTZ) announced that it will release results of operations for the quarter ended March 31, 2016 after the market closes on Thursday, May 5, 2016. Senior Management will also hold a conference call to discuss these results on Friday, May 6, 2016, at 9:00 a.m. Eastern time.

ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) caters to the Healthcare space. Its weekly performance is -1.82%. On the last day of trading company shares ended up at $1.08. ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) distance from 50-day simple moving average (SMA50) is -5.19%.

On 19 April, ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), announced that it has dosed the first healthy volunteer in the Phase 1b portion of the Company’s Phase 1b/2a multiple ascending dose clinical study of CMX157, ContraVir’s novel, highly potent lipid conjugate of tenofovir for treating hepatitis B virus (HBV) infection.

Leave a Reply

Your email address will not be published. Required fields are marked *